HubSpot (HUBS) Q3 2026 Earnings Call Transcript

HubSpot reported Q3 revenue of $947.6 million, up 17% year over year, and non-GAAP operating margin of 23%, up 3 percentage points; non-GAAP diluted EPS rose 43% to $3.81. However, Q4 revenue guidance of $945 million to $947 million implies 12% growth, and management expects FY2026 net new ARR to decline year over year as budget sensitivity and longer sales cycles persist into 2027. The company repurchased $237.2 million of stock in Q3, bringing 2026 year-to-date repurchases to nearly $1 billion, while continuing to target a 23%–24% non-GAAP operating margin in 2027.

Analysis

The key issue is conversion, not AI engagement. Trial growth, connector activity and credit consumption are leading indicators, but they do not yet establish paid conversion, incremental gross profit or durable expansion. Higher retention among connector users may reflect customer selection rather than causal uplift. Meanwhile, pricing simplification can improve acquisition and product reach while lowering initial revenue per account; more hands-on implementation may also raise the cost to convert trials. That combination puts pressure on growth quality before it shows up in headline usage metrics.

Near term, the guide and management’s expectation of continued pressure into 2027 make estimates vulnerable to further cuts; buybacks and margin discipline can support EPS without resolving weaker net upgrades and declining net new ARR. Over 1–3 months, watch Q4 net adds, NRR, trial-to-paid conversion and EMEA pilot results. Over 6–18 months, the test is whether credit monetization and retention gains offset lower starting ASPs and shifting discovery away from inbound. Salesforce is a plausible competitive benchmark for enterprise CRM budgets, but HubSpot’s SMB exposure makes it an imperfect hedge.

Contrarian case: lower entry friction and connectors could broaden adoption and improve retention before revenue reaccelerates. However, elevated usage from a low base is not proof of monetization. The thesis weakens if NRR stabilizes or improves, net new ARR returns to growth, and management demonstrates paid AI expansion without sustained ASP dilution or margin slippage.

Key Decisions for Investors

• Keep HUBS underweight; avoid chasing reported AI usage as a revenue proxy. For a tactical bearish expression, scale into a short on post-earnings relief rallies rather than selling into an opening gap; do not set a price target without current valuation and price data.
• Consider a defined-risk HUBS put spread only if implied volatility and event pricing are reasonable; otherwise the February 2027 results are a cleaner catalyst checkpoint than paying elevated premium now.
• Track Q4 and February disclosures for trial-to-paid conversion, credit revenue or consumption monetization, NRR, net new ARR, customer adds and the broader EMEA pricing-pilot read-through. Treat usage growth alone as insufficient confirmation.
• Falsify the cautious thesis if NRR turns higher, net new ARR resumes growth, and AI-led expansion is demonstrated alongside stable margins; renewed deterioration in NRR or weaker-than-expected customer additions would reinforce it.